Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a prospective, multi-center, single arm, non-randomized study to define safety and efficacy of the Veniti Vici™ Venous Stent System in relation to pre-defined Objective Performance goals. A maximum of 200 patients at up to 45 centers worldwide will be enrolled. Thirty (30) feasibility patients will be enrolled at approximately 7-10 centers and 170 pivotal patients will be enrolled at approximately 45 centers worldwide. The follow-up period is 36 months.
Full description
The objective of this prospective study is to assess the safety and efficacy of the Veniti Vici™ Venous Stent System in achieving patency of the target venous lesion in patients who present with clinically significant chronic non-malignant obstruction of the iliofemoral venous outflow tract.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria - Pre-Procedure Criteria:
Age ≥ 18 years
Willing and capable of complying with all follow-up evaluations at the specified times
Able and willing to provide written informed consent prior to study-specific procedures
Presence of unilateral, clinically significant, chronic non-malignant obstruction of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof, defined as a ≥50% reduction in target vessel lumen diameter (to be measured by venogram during procedure)
Clinically significant venous obstruction defined as meeting at least one of the following clinical indicators:
Negative pregnancy test in females of child-bearing potential
Intention to stent the target lesion only with the Veniti Vici Venous Stent
Exclusion Criteria - Pre-Procedure Criteria:
Presence or history of clinically significant pulmonary emboli within 6 months prior to enrollment.
Venous obstruction that extends into the inferior vena cava (IVC)
Contralateral disease of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof with planned treatment within 30 days after subject enrollment
Life expectancy <12 months
Female of childbearing potential who is pregnant or plans to become pregnant during the duration of the clinical study
Uncontrolled or active coagulopathy OR known, uncorrectable bleeding diathesis with the following definitions:
Uncorrected hemoglobin of ≤ 9 g/dL
Patients with an estimated glomerular filtration rate (eGFR) <30 mL/min. In patients with diabetes mellitus, eGFR <45 mL/min.
Known hypersensitivity to nickel or titanium
Contrast agent allergy that cannot be managed adequately with pre-medication
Intended concurrent thrombolysis or thrombectomy procedure OR intended or planned (within 30 days) adjuvant procedure such as creation of temporary arteriovenous fistula, placement of IVC filter, endovenectomy or saphenous vein ablation
Current or recent (within 30 days) active participation in another drug or device clinical trial (Participation in observational studies is acceptable.)
Patient judged to be a poor candidate by the primary investigator
Patients who have had any prior surgical or endovascular intervention of the target vessel [Note: Patients who have had catheter-directed or mechanical thrombolysis in the target vessel for DVT at least 3 month (90 days) prior to the VIRTUS index procedure may be included in the trial.]
Exclusion Criteria - Intra-Procedural Criteria:
Primary purpose
Allocation
Interventional model
Masking
200 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal